KR20020020536A - Injection for impotency - Google Patents

Injection for impotency Download PDF

Info

Publication number
KR20020020536A
KR20020020536A KR1020000053758A KR20000053758A KR20020020536A KR 20020020536 A KR20020020536 A KR 20020020536A KR 1020000053758 A KR1020000053758 A KR 1020000053758A KR 20000053758 A KR20000053758 A KR 20000053758A KR 20020020536 A KR20020020536 A KR 20020020536A
Authority
KR
South Korea
Prior art keywords
injection
erection
penis
volume
prostagladin
Prior art date
Application number
KR1020000053758A
Other languages
Korean (ko)
Inventor
장우영
Original Assignee
장우영
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 장우영 filed Critical 장우영
Priority to KR1020000053758A priority Critical patent/KR20020020536A/en
Publication of KR20020020536A publication Critical patent/KR20020020536A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

PURPOSE: A composition for inducing penile erections containing phentolamine and verapamil together with conventional prostaglandin E1 is provided which can produce and maintain a penile erection in a male suffering from erectile dysfunction by injection. CONSTITUTION: A mixture of 5 to 10% by volume of phentolamine methylate, 40 to 80.00% by volume of verapamil hydrochloric acid and 10 to 55.00% by volume of distilled water is blended with 0.005 to 1.5% by volume of conventional prostaglandin E1. The composition generates no fibrosis of the corpus cavernosum penis during long-term use and reduces pain after injection.

Description

발기유발제{INJECTION FOR IMPOTENCY}Erection triggers {INJECTION FOR IMPOTENCY}

본 발명은 인체의 음경이 제대로 발기되지 않는 발기부전 환자에 사용되는 발기유발제에 관한 것으로서, 보다 상세하게는 음경외부에 직접 투여하여 음경을 효과적으로 발기함과 더불어 통증을 저감하고 발기의 강직도를 증대하며 보관 사용하는 기간을 증대할 수 있도록 하는 발기유발제에 관한 것이다.The present invention relates to an erectile trigger used in an erectile dysfunction patient whose penis is not properly erected, and more particularly, directly administered to the outside of the penis to effectively erect the penis, reducing pain and increasing stiffness of the erection. It relates to an erectile propellant that can increase the shelf life.

일반적으로 발기는 성적 충동 등을 느끼면 스폰지 모양의 음경해면체 내의 동맥으로부터 혈액이 충만되고 평활근의 이완과 정맥의 압박으로 잠시 혈류가 빠져나가지 못해 해면체 내압이 상승되는 것이다.In general, when an erection is a sexual urge, blood is filled from an artery in a sponge-like corpus cavernosum, and the intracavernosal pressure is increased due to the relaxation of the smooth muscle and the compression of the vein.

그리고 남성의 발기부전은 혈류의 공급이 안되거나 불충분할 때, 공급이 되더라도 정맥으로 혈류 차단이 되지 않을 때, 유출될 때에 해면체 내압이 상승되지 않거나 불충분하여 만족할 정도로 일정시간동안 유지되지 않을 때 등에 의하여 발생하며, 인체의 음경이 발기되지 않는 경우, 발기가 되더라도 성교하기에 충분할 정도로 발기되지 않는 경우, 그리고 발기된 상태에서 발기의 지속 시간이 매우 짧은 경우 등으로 대별되며, 발기부전의 범위는 음경 강직의 부분적인 감소에서부터 지속적인 발기유지불능으로 인한 완전한 발기실패까지 다양한 양상을 나타내고 있다.And men's erectile dysfunction is due to when the blood supply is insufficient or insufficient, when the supply is not blocked by the vein even when supplied, when the intracavernosal pressure is not elevated or is insufficient or maintained for a certain time. If the penis of the human body does not have an erection, even if the erection is not enough to have sex, and the duration of the erection is very short in the erection state, the extent of erectile dysfunction is penile stiffness This can range from a partial reduction in severity to complete erection failure due to sustained impotence.

물론 발기부전 환자를 위해서는 진공압축장치, 혈관수술, 음경보철기구, 성심리요법, 호르몬요법 및 혈관확장제의 투여 등이 있다.Of course, for patients with erectile dysfunction, there is a vacuum compressor, angioplasty, penile prosthesis, sexual psychotherapy, hormone therapy, and vasodilator.

여기서는 상기 혈관확장제를 음경해면체 내로 투여하는 방법이 대다수의 환자에게 신속한 발기를 유발하여 매우 성공적인 방법으로 이용되는 바, 혈관확장제를 투여하는 방법의 일 예로는 통증에 따른 심리적 불안, 불편함, 외기의 균에 의한 감염, 음경의 섬유화, 저혈압 및 지속발기 등의 부작용이 발생할 수 있으나, 음경해면체 내로 직접 주사하는 방법이 많이 이용된다.Here, the method of administering the vasodilator into the corpus cavernosum causes a rapid erection in a large number of patients and is used as a very successful method. Examples of the method of administering the vasodilator include psychological anxiety, discomfort, and external air caused by pain. Side effects such as infection by bacteria, fibrosis of the penis, hypotension and sustained erection may occur, but a method of directly injecting into the corpus cavernosum is used.

그래서 종래에는 음경에 사용되는 혈관확장제로는 프로스타글라딘 E1(PROSTAGLARDIN E1)이 사용되며, 이는 발기부전 환자의 음경해면체에 직접 투여하여 환자의 음경을 발기시키고 발기 상태를 일정한 시간동안 유지시킨다.Thus, conventionally, vasodilators used in the penis are used as prostagladin E 1 (PROSTAGLARDIN E 1 ), which is directly administered to the corpus cavernosum of erectile dysfunction patients to erect the patient's penis and maintain an erection state for a certain time. Let's do it.

그러나 종래에는 상기 프로스타글라딘 E1을 투여한 환자가 '프로스타글라딘 E1이 투여된 뒤에 혈액과 반응하는 동안에 통증이 발생한다'고 호소하게 되는 단점이 있다.However, the prior art has the disadvantage that the said prostaglandin E the patients treated with 1 appeal and "prostaglandin E 1 and a pain occurs during the reaction with blood after the administration.

또한 분말상태의 프로스타글라딘 E1이 수용액과 혼합되어 환자에게 사용되기 때문에, 수용액 상태로 된 뒤에 보존기간이 짧다는 단점이 더 있다.In addition, since the prostagladin E 1 in powder form is mixed with the aqueous solution and used by the patient, there is a further disadvantage that the shelf life is short after the aqueous solution is formed.

특히 프로스타글라딘 E1은 강도가 약해서 전체 발기부전환자의 30％정도에만 만족한 효과를 나타낸다는 단점이 있다.In particular, the prostagladin E 1 has a weak strength, the disadvantage is that only about 30% of the total erectile dysfunction exhibits a satisfactory effect.

더우기 파파베린을 혼합 사용하여 음경에 투여하면 음경의 강도를 증대시킬 수 있으나, 장기간 사용시에 음경의 섬유화와 같은 심각한 부작용을 초래할 수 있게 된다.Furthermore, mixed administration of papaverine to the penis may increase the strength of the penis, but may cause serious side effects such as fibrosis of the penis over long periods of use.

본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위하여 안출된 것으로서, 본 발명의 목적은 공지의 프로스타글라딘 E1에 다른 약제를 첨가하여 음경에 직접 투여함으로써, 투여한 뒤에 발생할 수 있는 통증을 저감하고, 부작용없이 음경을 효과적으로 발기하며, 보관 사용하는 기간을 증대할 수 있는 발기유발제를 제공하는 데 있다.The present invention has been made to solve the above problems of the prior art, an object of the present invention by adding another agent to the known prostagladin E 1 directly administered to the penis, pain that may occur after administration It is to provide an erectile propellant that can reduce the risk, effectively erect penis without side effects, and increase the shelf life.

따라서 본 발명은 상기와 같은 목적을 달성하기 위하여, 혈관확장제인 프로스타글라딘 E1으로 이루어지는 공지의 발기유발제에 있어서, 펜톨아민메틸레이트 5％ ∼ 10％, 염산베라파밀 40％ ∼ 80.00％, 그리고 주사용 증류수 10％ ∼ 55.00％를 부피비로 혼합한 뒤, 상기 프로스타글라딘 E1을 상기 혼합물의 중량의 0.005％ ∼ 1.5％를 혼합하는 것으로 이루어지는 발기유발제를 제공한다.Therefore, in order to achieve the above object, the present invention provides a known erectile agent comprising prostagladin E 1 , which is a vasodilator, 5% to 10% of phentolamine methylate, 40% to 80.00% of verapamil hydrochloride, and After providing 10%-55.00% of distilled water for injection, the prostagladin E 1 is mixed with 0.005%-1.5% of the weight of the mixture.

이하 본 발명에 의한 발기유발제에 대하여 상세하게 설명한다.Hereinafter, the erection-producing agent according to the present invention will be described in detail.

본 발명에 의한 발기유발제는 음경의 혈관확장제인 공지의 프로스타글라딘 E1(PROSTAGLARDIN E1), 혈관확장제 겸 고혈압치료제인 펜톨아민메틸레이트 (PHENTOLAMIN), 그리고 혈관확장제 겸 고혈압치료제인 염산베라파밀(VERAPAMILE)을혼합함과 더불어 주사용 증류수를 포함하는 것으로 이루어진다.Erection inducer according to the present invention of the vasodilator of the penis known prostaglandin E 1 (PROSTAGLARDIN E 1), vasodilators President and anti-hypertensive agent is phentolamine amine methylate (PHENTOLAMIN), and vasodilators President and anti-hypertensive agent is verapamil hydrochloride ( VERAPAMILE) as well as containing distilled water for injection.

즉 본 발명에서는 펜톨아민메틸레이트 5％ ∼ 10％, 염산베라파밀 40％ ∼ 80.00％, 그리고 주사용 증류수 10％ ∼ 55.00％를 부피비로 혼합한 뒤, 상기 프로스타글라딘 E1을 상기 혼합물의 중량의 0.005％ ∼ 1.5％를 혼합하는 것이며, 주사용 증류수를 포함할 수 있는 바, 이는 상기 프로스타글라딘 E1, 펜톨아민메틸레이트 및 염산베라파밀의 혼합물의 강도를 조정하기 위한 것이다.Namely, in the present invention, 5% to 10% of pentolamine methylate, 40% to 80.00% of verapamil hydrochloride, and 10% to 55.00% of distilled water for injection are mixed in a volume ratio, and the prostagladin E 1 is added to the weight of the mixture. It is a mixture of 0.005% to 1.5% of, and may contain distilled water for injection, which is to adjust the strength of the mixture of the prostagladin E 1 , phentolamine methylate and verapamil hydrochloride.

이와 같이 이루어지는 발기유발제는 다음과 같이 작용하게 되며, 본 실시예에서는 프로스타글라딘E1100㎍, 펜톨아민메틸레이트 1㏄ 및 염산베라파밀 8㏄ 혼합한 것을 사용하게 되고, 주사용 증류수 2㏄를 첨가할 수 있으며, 액체 상태로 혼합하여 주사액으로 적당량 사용하게 된다.The erection-producing agent thus formed acts as follows. In this embodiment, a mixture of 100 μg of prostagladin E 1 , 1 펜 of pentolamine methylate, and 8 ㏄ of verapamil hydrochloride is used, and 2 ㏄ of distilled water for injection is used. It can be added, mixed in a liquid state and used as an appropriate amount for injection.

그리고 본 실시예에서는 편의상 비(B)그룹, 씨(C)그룹, 디(D)그룹 및 이(E)그룹으로 구분하게 되며, 상기 비(B)그룹은 음경이 발기되나 발기 상태를 지속하지 못하는 그룹이고, 상기 씨(C)그룹은 음경의 발기 정도 즉 강직의 정도가 50％이하로서 완전히 발기하지 못하는 그룹이고, 상기 이그룹(E)은 거의 발기되지 않고 수술 직선에 도래한 그룹이며, 상기 디그룹(D)은 상기 씨그룹과 이그룹 사이의 음경 상태를 나타내는 그룹으로 구분한 것이다.In the present embodiment, for convenience, the non-B group, the C group, the D group, and the E group are classified into the non-B group. The group (C) is a group where the erection of the penis, that is, the degree of stiffness is less than 50%, and the erectile group is not fully erected. The D group (D) is divided into groups representing the penis state between the C group and the two groups.

물론 상기 프로스타글라딘 E1은 가루이고 펜톨아민메틸레이트과 염산베라파밀은 액체이므로 약제를 상호 혼합하여 액제로 만든 뒤, 액제를 인체의 음경에 투여하게 되며, 그 투여량은 나이, 체중, 일반적인 건강상태, 투여시간 및 경로, 배설속도, 병용 약물의 양, 치료할 특정 질병의 경중 등에 따라 달라질 수 있으며, 미리 환자를 충분히 진단한 뒤에 조정함이 바람직하다.Of course, the prostagladin E 1 is a powder and phentolamine methylate and verapamil hydrochloride are liquids, so the drugs are mixed with each other to form a liquid, and then the liquid is administered to the penis of the human body. It may vary depending on the condition, the time and route of administration, the rate of excretion, the amount of concomitant medication, the severity of the particular disease to be treated and the like.

비(B)그룹B group 일련번호Serial Number 나 이(세)Age (years) 투여량(cc)Dose (cc) 지속시간(분)Duration (minutes) 1One 2727 0.20.2 6060 22 3030 0.240.24 6060 33 4040 0.160.16 8080 44 4141 0.180.18 6060 55 4343 0.10.1 6060 66 4444 0.250.25 6060 77 4545 0.060.06 6060 88 4747 0.20.2 6060 99 4848 0.140.14 8080 1010 5050 0.160.16 6060 1111 5151 0.120.12 8080 1212 5252 0.250.25 6060 1313 5353 0.20.2 6060 1414 5454 0.060.06 6060 1515 5555 0.180.18 6060 1616 5858 0.30.3 6060 1717 6161 0.170.17 5050 1818 6363 0.260.26 6060

상기 도표에서 인식할 수 있듯이, 40대와 50대에 주로 분포되어 있고, 투여량이 환자의 나이에 비례하는 것이 아니며, 지속시간도 나이에 따라 다양하게 분포된 것으로서, 환자의 다양한 건강 상태가 무엇보다도 중요한 것이다.As can be seen from the above chart, it is mainly distributed in the 40s and 50s, the dosage is not proportional to the age of the patient, the duration is also distributed in various ages, the various health conditions of patients It is important.

즉 본 발명에 의한 발기유발제는 상기 도표에서 나타난 바와 같이 0.06cc ∼ 0.26cc를 투여할 경우에 완전히 발기된 상태에서 보통 60분 이상 지속됨을 알 수 있으며, 그 지속시간을 줄이기 위해서는 발기유발제의 투여량을 작게 하거나 주사용 증류수를 첨부하여 투여함이 바람직하다.In other words, the erectile trigger according to the present invention can be seen that usually lasts more than 60 minutes in a fully erected state when administered 0.06cc to 0.26cc, as shown in the table above, in order to reduce the duration It is preferable to make small or to add distilled water for injection.

씨(C)그룹C Group 일련번호Serial Number 나 이(세)Age (years) 투여량(cc)Dose (cc) 지속시간(분)Duration (minutes) 1One 3030 0.240.24 8080 22 3737 0.270.27 5050 33 4141 0.240.24 5050 44 4545 0.350.35 6060 55 4747 0.340.34 4040 66 5050 0.350.35 6060 77 5050 0.220.22 5050 88 5151 0.30.3 6060 99 5555 0.350.35 6060 1010 5858 0.350.35 6060 1111 6060 0.30.3 4040 1212 6363 0.30.3 5050 1313 6464 0.30.3 4040 1414 6565 0.340.34 3030 1515 7171 0.340.34 4040

상기 도표에서 인식할 수 있듯이, 50대와 60대에 주로 분포되어 있고, 투여량이 상술한 비(B)그룹의 환자보다 나이의 분포가 상승함을 알 수 있고, 지속시간도 저하됨을 알 수 있다.As can be seen from the above diagram, it is mainly distributed in the 50s and 60s, the dosage is higher than the above-mentioned patients in the non- (B) group, it can be seen that the distribution of age is increased, the duration is also reduced. .

씨(D)그룹C Group 일련번호Serial Number 나 이(세)Age (years) 투여량(cc)Dose (cc) 지속시간(분)Duration (minutes) 1One 3030 0.40.4 4040 22 5050 0.40.4 5050 33 5353 0.40.4 5050 44 5858 0.450.45 5050 55 6363 0.40.4 5050

이(E)그룹E Group 일련번호Serial Number 나 이(세)Age (years) 투여량(cc)Dose (cc) 지속시간(분)Duration (minutes) 1One 5050 0.50.5 3535 22 5858 0.480.48 4040 33 6767 0.50.5 4040

두 개의 상기 도표에서 인식할 수 있듯이, 디(D)그룹과 이(E)그룹에 속하는 나이의 분포는 알 수 없으나, 투입량이 0.4cc ∼ 0.5cc의 분포를 형성하고 있으며, 발기된 상태에서 지속되는 시간이 감소함을 알 수 있다.As can be seen from the two charts above, the distribution of ages belonging to the D and D groups is unknown, but the inputs form a distribution of 0.4 cc to 0.5 cc and persist in the erection state. It can be seen that the time required to decrease.

즉 발기의 기능이 50％이상 저하된 경우에서부터 수술직전 상태의 경우까지는 약물의 투여량을 증대하더라도 발기된 상태에서의 지속시간이 저하된다는 것을 알 수 있는 것이다.That is, even if the function of the erection is reduced by more than 50% to the state just before surgery, even if the dose of the drug is increased, the duration in the erection is reduced.

이와 같이 본 발명의 발기유발제는 0.04cc ∼ 0.8cc을 투여할 수 있는데, 투여량이 0.04cc미만일 경우에는 음경을 용이하게 발기하여 발기된 상태를 지속하기 힘들거나 지속하더라도 지속시간이 짧게 되는 것이며, 투여량이 0.8cc을 초과할 경우에는 너무 많은 기간의 지속을 유지할 수 있을 뿐만 아니라 과다투여로 인한 부작용이 발생할 수 있는 것이다.As described above, the erectile trigger of the present invention can be administered 0.04cc to 0.8cc, when the dosage is less than 0.04cc, the penis is easily erected, so that even if the erection is difficult or sustained, the duration is shortened. If the amount exceeds 0.8cc can not only maintain too much duration but also side effects due to overdose.

이렇게 본 발명의 발기유발제는 비록 발기부전을 치료하지는 못하더라도 더욱 악화되는 것을 방지하면서 발기지속시간을 만족할 정도로 유지할 수 있다.Thus, the erectile trigger of the present invention can be maintained to satisfy the erection duration while preventing further worsening, even if the erectile dysfunction is not treated.

이상 설명한 바와 같이, 본 발명에 의한 발기유발제는 안전한 약제인 다른 약제를 프로스타글라딘 E1에 첨가하여 음경에 직접 투여하기 때문에, 투여한 뒤에 발생할 수 있는 통증을 저감하게 된다는 이점이 있다.As described above, the erection-producing agent according to the present invention has the advantage of reducing the pain that may occur after administration because it is directly administered to the penis by adding another drug, which is a safe drug, to prostagladin E 1 .

또한 본 발명의 주입약제는 음경에 직접 투여할 수 있어 음경을 효과적으로 발기시키며, 약제가 액체 상태로 오랫동안 보관하여 사용할 수 있으며, 장기간 사용시에 음경의 섬유화 등과 같은 부작용이 발생하지 않는다는 다른 이점이 있다.In addition, the injectable drug of the present invention can be directly administered to the penis to effectively erect the penis, the drug can be stored and used for a long time in a liquid state, there is another advantage that does not occur side effects such as fibrosis of the penis during long-term use.

더우기 프로스타글라딘, 펜톨아민메틸레이트, 염산베라파밀 그리고 주사용 증류수를 혼합한 액체의 투입양이 극소량이기 때문에, 고혈압이나 부정맥 등의 심장 혈관 질환자에게도 투여할 수 있고, 주사용 증류수로 혼합물을 조정할 수 있어서 사용 약물의 강도를 조정할 수 있으며, 90％이상의 발기부전 환자(편의상 B,C,D,E그룹의 환자)에게 적용할 수 있다는 또다른 이점이 있다.Furthermore, since the amount of liquid mixed with prostagladin, phentolamine methylate, verapamil hydrochloride and distilled water for injection is very small, it can be administered to cardiovascular patients such as hypertension or arrhythmia, and the mixture is adjusted with distilled water for injection. It is possible to adjust the strength of the drug to be used, there is another advantage that can be applied to more than 90% erectile dysfunction patients (patients of groups B, C, D, E for convenience).

Claims (1)

혈관확장제인 프로스타글라딘 E1으로 이루어지는 공지의 발기유발제에 있어서,In a known erectile agent comprising a prostaglandin E 1 which is a vasodilator, 펜톨아민메틸레이트 5％ ∼ 10％, 염산베라파밀 40％ ∼ 80.00％, 그리고 주사용 증류수 10％ ∼ 55.00％를 부피비로 혼합한 뒤, 상기 프로스타글라딘 E1을 상기 혼합물의 중량의 0.005％ ∼ 1.5％를 혼합하는 것으로 이루어지는 발기유발제.After mixing 5% to 10% of pentolamine methylate, 40% to 80.00% of verapamil hydrochloride, and 10% to 55.00% of distilled water for injection, the prostagladin E 1 was added at 0.005% to the weight of the mixture. An erection inducing agent comprising 1.5% mixed.
KR1020000053758A 2000-09-09 2000-09-09 Injection for impotency KR20020020536A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020000053758A KR20020020536A (en) 2000-09-09 2000-09-09 Injection for impotency

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000053758A KR20020020536A (en) 2000-09-09 2000-09-09 Injection for impotency

Publications (1)

Publication Number Publication Date
KR20020020536A true KR20020020536A (en) 2002-03-15

Family

ID=19688447

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020000053758A KR20020020536A (en) 2000-09-09 2000-09-09 Injection for impotency

Country Status (1)

Country Link
KR (1) KR20020020536A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940001890A (en) * 1992-07-20 1994-02-16 한스-게오르그 우르바흐, 랄프 물레이 Use of 1,2,5-oxadiazole-2-oxide to treat erectile dysfunction
WO1998052569A1 (en) * 1997-05-19 1998-11-26 Zonagen, Inc. Combination therapy for modulating the human sexual response
KR19990008131A (en) * 1995-04-28 1999-01-25 죠셉 에스. 포돌스키 Methods and preparations for regulating a person's sexual response
KR100195348B1 (en) * 1996-10-31 1999-06-15 장용택 Injectable composition containing stable prostaglandin e1
KR19990069591A (en) * 1998-02-11 1999-09-06 이영훈 Sexual Dysfunction Therapeutics and Treatment Methods
WO1999065303A1 (en) * 1998-06-15 1999-12-23 Macrochem Corporation Composition and method for treating penile erectile dysfunction
KR20010045152A (en) * 1999-11-03 2001-06-05 안종훈 A remedy for inducting the erection

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940001890A (en) * 1992-07-20 1994-02-16 한스-게오르그 우르바흐, 랄프 물레이 Use of 1,2,5-oxadiazole-2-oxide to treat erectile dysfunction
KR19990008131A (en) * 1995-04-28 1999-01-25 죠셉 에스. 포돌스키 Methods and preparations for regulating a person's sexual response
KR100195348B1 (en) * 1996-10-31 1999-06-15 장용택 Injectable composition containing stable prostaglandin e1
WO1998052569A1 (en) * 1997-05-19 1998-11-26 Zonagen, Inc. Combination therapy for modulating the human sexual response
KR19990069591A (en) * 1998-02-11 1999-09-06 이영훈 Sexual Dysfunction Therapeutics and Treatment Methods
WO1999065303A1 (en) * 1998-06-15 1999-12-23 Macrochem Corporation Composition and method for treating penile erectile dysfunction
KR20010045152A (en) * 1999-11-03 2001-06-05 안종훈 A remedy for inducting the erection

Similar Documents

Publication Publication Date Title
FI102454B (en) A process for the preparation of compositions for the treatment of erectile dysfunction
US5891915A (en) Method for enhancing female sexual response and an ointment therefor
US6200591B1 (en) Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
JP3513764B2 (en) Compositions and methods for treating penile erectile dysfunction
US9968479B2 (en) System and method for treating erectile dysfunction
US6031002A (en) Method for enhancing female sexual response and a composition therefor
CZ281897A3 (en) Topic water based cream containing nitroglycerine, process of its preparation and use
US20050276865A1 (en) Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
KR19980703052A (en) Methods and kits for preventing erectile dysfunction
EA010885B1 (en) Pharmaceutical compositions and methods for insulin treatment
Chao et al. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction
US6809079B2 (en) Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
US7513879B2 (en) Noninvasive angioplasty using momentary vacuum therapy
US20230414488A1 (en) Sensitization cream comprising l-arginine and l-citrulline and therapeutic uses thereof
KR20020020536A (en) Injection for impotency
KR20020018205A (en) Injection for impotency
US20090257956A1 (en) Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation
CA2243657C (en) Compositions for treatment of erectile dysfunction
Hayes et al. Assessment of penile erection methods in rhesus macaques to model pharmacokinetics of antiretroviral drugs and penile infection with simian immunodeficiency virus
KR20050057245A (en) Methods of treatment of male erectile dysfunction
WO2001035945A2 (en) Use of prostaglandin a2 for the treatment and prophylaxis of priapism
SAULIE et al. Treating erectile dysfunction in diabetes patients
Campbell Treating erectile dysfunction
Beauchesne Male erectile dysfunction
IT201600119871A1 (en) USE OF THE ASSOCIATION OF INHIBITORS OF PHOSPHODIESTERASE 5 WITH PROSTAGLANDIN E1 FOR THE TREATMENT OF THE ERECTILE DYSFUNCTION

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application